What Curetopia does

Curetopia is a Swiss non-profit association (verein) and the first biotech Decentralized Autonomous Organization (BioDAO) focused on eradicating rare genetic diseases through decentralized science. Founded in 2024 by Ethan O. Perlstein, Ph.D. (also founder of Perlara PBC), the organization enables on-chain governance of rare disease research by patient communities, scientists, and DeSci supporters via the $CURES governance token issued on Solana (100M total supply). Its core scientific platform leverages Saccharomyces cerevisiae yeast as a model organism for high-throughput drug repurposing, using genetically engineered 'yeast-patient avatars' that carry patient-specific mutations to screen an 8,400-compound TargetMol library of FDA-approved drugs, nutraceuticals, and OTC supplements. Curetopia has prospectively identified nearly 800 inherited metabolic diseases as addressable through this yeast-based approach, with a 2025 roadmap to scale from one pilot disease to 60.

Curetopia's business model operates across multiple potential revenue streams: direct-to-consumer commercial spinouts of nutraceutical combination therapies (modeled on VitaDAO's Blueprint), biopharma licensing of drug repurposing candidates and IP-NFTs, mission-aligned investments in allied rare disease platforms (such as Unravel Biosciences), and potential Priority Review Voucher value of approximately $150M contingent on US regulatory reauthorization. The organization employs 1-to-N decentralized observational clinical trials as a low-cost alternative to traditional institutional studies, with anti-shelving smart contract provisions designed to prevent promising programs from being abandoned.

The organization serves three primary customer segments: rare disease patient communities and families seeking research funding, researchers and clinicians needing capital for underserved programs, and the DeSci/crypto community seeking transparent, mission-driven investment vehicles. Curetopia raised $1.77 million through community crowdfunding in December 2024, attracting over 1,000 participants to fund its pilot AARS2 deficiency project. Core operational partnerships include Perlara PBC (yeast screening laboratory), BIO Protocol (DeSci infrastructure), CombinedBRAIN (120+ neurodevelopmental disorder affiliates), and the CureARS Foundation (AARS2 patient community).

Name

Curetopia

Legal name

Curetopia Association

Website

https://curetopia.xyz

Company type

Private

Founded year

2024

Operating status

Operating

Headcount range

1–10 employees

Short description

Curetopia is a Swiss BioDAO that funds rare disease drug repurposing research through community-governed token-based decision-making on Solana, using yeast-powered screening of 8,400 compounds to identify repurposing candidates for inherited metabolic diseases affecting underserved patient communities.

Ownership category

akta.pro rank

Product category

Rare Disease Research

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Voluntary Health Organizations (813212)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Global Health Research, Evidence & Technical Assistance Organizations (HLAJAKAN)

akta.pro secondary industries

Health & Medical Research Grantmaking Foundations (BPAGAKAL), Public Health Financing, Budgeting & Grants Management (HLAJAMAC)

Keywords

• Drug repurposing
• Rare disease research
• Decentralized science
• Biotech governance
• Patient communities

Headquarters

HQ city

Zug

HQ country

Switzerland

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B and B2C

Offering type

Services

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Direct-to-Consumer Commercial Spinouts: Revenue generated from selling proprietary combination therapies (nutraceutical stacks) directly to consumers via commercial spinouts, similar to VitaDAO's Blueprint model. Initial focus on inherited metabolic diseases where drug repurposing screens consistently yield nutraceutical candidates.
2. Biopharma Licensing Deals: Income from licensing drug repurposing candidates, IP-NFTs, and therapeutic modalities to biopharma companies. Rare disease research funded by Curetopia results in IP ownership rights that may be monetized through B2B licensing arrangements.
3. Mission-Aligned Investments: Income from strategic investments in allied rare disease platform companies or projects, such as Unravel Biosciences, capturing upside potential in partner organizations.
4. Priority Review Voucher (PRV) Value: Potential $150M market incentive from PRV reauthorization for developing medicines for rare pediatric diseases, representing a long-term value creation pathway contingent on US regulatory reauthorization.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

Core offering

Curetopia operates as a BioDAO (Biotech Decentralized Autonomous Organization) structured as a Swiss non-profit association that funds and conducts rare disease research through on-chain governance. The organization uses yeast-powered drug repurposing screens (Saccharomyces cerevisiae model organisms) against an 8,400-compound library to identify existing drugs, nutraceuticals, and supplements with therapeutic potential for rare genetic diseases. Community members govern research direction and IP outcomes via the $CURES governance token on Solana.

Product overview

Curetopia is a BioDAO (Biotech Decentralized Autonomous Organization) structured as a Swiss non-profit association (verein) that combines decentralized governance with scientific research to eradicate rare diseases. The platform consists of the Curetopia DAO Platform (governance infrastructure), the $CURES token (utility and governance token enabling community participation), and the Yeast Drug Repurposing Platform (scientific research infrastructure operated by partner laboratory Perlara). The AARS2 Drug Repurposing Project serves as Curetopia's pilot research initiative. Additional offerings include the Curetopia Journal (editorial content platform) and Community Auction (token distribution mechanism). The platform enables patients, families, scientists, and supporters to collectively fund, govern, and advance rare disease research through on-chain voting and token-based governance.

Differentiator

Problem solved

Functional benefit

Products and services

• Curetopia DAO Platform On-chain governance platform enabling rare disease patient communities, scientists, and DeSci enthusiasts to vote on research proposals, funding allocations, and intellectual property decisions. Token holders control the fate of IP created from community-sponsored research through transparent, community-driven processes.
• $CURES Token Utility and governance token with a total supply of 100,000,000 tokens. Enables community members to vote on DAO actions and participate in research governance. Allocates 20% to core team (with vesting), 40% to treasury reserves, 15% to community auction, 10% to future token sales, 7% to service providers, 7% to community incentives, and 1% to airdrops.
• Yeast Drug Repurposing Platform Scientific research platform that leverages Saccharomyces cerevisiae (baker's yeast) as a model organism for high-throughput drug repurposing screens. Partner laboratory Perlara conducts screening against an 8,400-compound TargetMol library to identify existing drugs, nutraceuticals, and supplements with therapeutic potential for rare genetic diseases. Has prospectively identified nearly 800 inherited metabolic diseases (8% of all known rare diseases) caused by loss-of-function mutations in evolutionarily conserved genes.
• AARS2 Drug Repurposing Project Pilot research project focused on identifying drug repurposing candidates for AARS2 deficiency (Progressive Leukoencephalopathy with Ovarian Failure) using yeast-patient avatars. Screens approximately 8,500 repurposable compounds to find treatments for rare kiddos affected by this mitochondrial disease. Funded through $1.77 million in community crowdfunding.

Quantifiable outcome

• 95% of 10,000+ rare diseases have no approved treatment, representing massive unmet need
• +4 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Six partnerships are on record, tiered core, major and minor.

• CureARS FoundationcoreStrategic or Co-development Partner · 9 December 2024CureARS Foundation is the patient community organization for the AARS2 project. The foundation represents families affected by aminoacyl-tRNA synthetase (ARS) diseases and is ready to spread word about research results to their micro-communities and organize rapid 1-to-N clinical testing in affected children.
• Perlara PBCcoreTechnology or IntegrationPerlara PBC is Curetopia's primary research partner and yeast-screening laboratory. Founded in 2014 as the world's first biotech Public Benefit Corporation, Perlara conducts high-throughput drug repurposing screens using yeast-patient avatars. Curetopia's AARS2 project is conducted at Perlara's laboratory in Alameda, CA, and builds on Perlara's decade of experience with yeast-powered drug discovery.
• BIO ProtocolcoreGTM or Marketing PartnerBIO Protocol is a DeSci Funding & Liquidity Protocol that provides support with tokenomics design, DAO formation, legal/regulatory advisory, and Web3 technology infrastructure. BIO received 7% of $CURES token supply as service provider compensation. BIO Protocol's launchpad hosted Curetopia's community auction on Solana.
• CombinedBRAINmajorStrategic or Co-development PartnerCombinedBRAIN (CB) is an umbrella foundation with 120+ neurodevelopmental disorder (NDD) rare disease community affiliates that share common research infrastructure including a biobank and a network of responsive clinicians willing to test drug repurposing candidates in collaboration with affected families. Curetopia is in active discussions to scale up drug repurposing for all rare disease communities through this partnership.
• Unravel BiosciencesmajorStrategic or Co-development PartnerUnravel Biosciences is a Boston-based company that has developed rareSHIFT, a fully decentralized, direct-to-patient drug repurposing protocol involving at-home nasal swab collection, RNAseq gene expression analysis, and computational screening for drug repurposing candidates. Curetopia views Unravel as an ideal investment opportunity and codevelopment partner for rare disease programs.
• Maggie's PearlminorStrategic or Co-development PartnerMaggie's Pearl is a joint venture between Perlara and a PMM2-CDG family foundation dedicated to advancing epalrestat (discovered through drug repurposing screens) to the global market. The venture culminated in a pivotal clinical trial in pediatric PMM2-CDG patients. This represents a model for how Curetopia-funded research could be commercialized.

Scale indicators10 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• VitaDAO: Pioneer longevity BioDAO using a $VITA governance token on Ethereum to fund and govern early-stage research, with on-chain IP via Molecule. The most established direct analogue to Curetopia's BioDAO model, differing by therapeutic area.
• Unravel Biosciences: Boston-based rare disease drug repurposing company with a decentralized, direct-to-patient rareSHIFT protocol; Curetopia lists Unravel as a codevelopment partner and investment target, making it a tightly overlapping peer.
• Molecule: DeSci platform that pioneered IP-NFTs and on-chain research funding; Curetopia is already a Molecule ecosystem partner, and the two share the same IP-tokenization infrastructure.
• Biovista: Commercial drug repurposing firm using systematic biological-data approaches to find new indications, including in rare diseases; comparable to Curetopia on the core repurposing thesis but operates as a traditional B2B services company.
• Healx: AI-driven drug repurposing company focused on rare diseases; comparable in mission and in repurposing methodology, though Curetopia uses yeast models and decentralized governance while Healx uses in-silico AI and traditional venture backing.
• BIO Protocol: DeSci launchpad and liquidity protocol that incubated Curetopia and hosted its community auction. Closely comparable as the funding-and-launch infrastructure layer for BioDAOs.
• ValleyDAO: DeSci DAO funding longevity and age-related disease research via IP-NFTs and token-based governance; another direct structural analogue operating in the BioDAO category.
• AthenaDAO: BioDAO focused on women's health and longevity research using a token-governed funding model; structurally identical to Curetopia (BioDAO + on-chain research funding) but with a different therapeutic focus.

Others

• CombinedBRAIN: Umbrella foundation for 120+ neurodevelopmental-disorder rare disease community affiliates that shares biobank and clinician infrastructure with Curetopia; functions as a community-distribution partner rather than a competitor, but operates in the same rare-disease space.

Broad incumbents

• Perlara PBC: Curetopia's core research partner and laboratory operator; founded by the same individual, it is the world's first biotech Public Benefit Corporation and runs the yeast-powered drug repurposing platform that Curetopia's pipeline depends on.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

• Xx.com/endrarediseases
• LinkedInlinkedin.com/company/curetopia

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Curetopia